This is a randomised, placebo-controlled, double-blinded, crossover pilot trial using novel brain imaging technology to comprehensively examine and localise differences in sleep and brain activation following a single dose of an oral cannabis extract in 20 patients with insomnia disorder.
Participants will receive all of the interventions (a single fixed dose of an oral cannabis extract or placebo) at random across two overnight sleep studies at the Woolcock Institute of Medical Research in Glebe. Each overnight sleep study will be scheduled at least one-week apart. The objective of this trial is to examine the efficacy of an oral cannabis extract on sleep, cognition and next-day function including driving performance in adults with insomnia disorder, compared to placebo.
This is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, and the Woolcock Institute of Medical Research.
Principal Investigators: Professor Ron Grunstein and Dr Camilla Hoyos (Woolcock Institute of Medical Research)
Project Coordinator: Anastasia Suraev (University of Sydney)
To get involved in the trial, check your suitability on the CANSLEEP Study website.
For more information, please contact the trial coordinator, Anastasia via email firstname.lastname@example.org or call 0439 804 551.